Stockscreener 앱 받기
10.00
5.37%
0.51
시간 외 거래:
9.71
-0.29
-2.90%
Vir Biotechnology Inc 주식(VIR)의 최신 뉴스
[144] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Vir Biotechnology Extends Reach with Astellas Collaboration on VIR-5500 - StocksToTrade
Vir Biotechnology leaps on news of Astellas collaboration - The Pharma Letter
Vir Biotechnology (VIR) Receives Maintained Overweight Rating Fr - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Vir Biotechnology plans $200 million stock offering - Investing.com India
Vir Biotechnology Announces Proposed Public Offering of Common Stock - BioSpace
A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update - Yahoo Finance
Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,089 Shares of Stock - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CEO Sells 19,039 Shares of Stock - MarketBeat
Verneuil Vanina De Sells 4,445 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 2,089 Shares of Stock - MarketBeat
Aug Big Picture: Can Vir Biotechnology Inc be recession proofJuly 2025 Chart Watch & AI Based Trade Execution Alerts - baoquankhu1.vn
VIR: Needham Raises Vir Biotechnology's Price Target in New Anal - GuruFocus
Vir Biotechnology’s Call Highlights Astellas Deal, VIR-5500 Momentum - TipRanks
Vir Biotechnology launches $200M public stock offering - MSN
These Stocks Are Today’s Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More - Barron's
VIR Stock Offering Managed by Leading Financial Firms - GuruFocus
Astellas, Vir Biotechnology form partnership on prostate cancer drug By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week high at 9.88 USD By Investing.com - Investing.com South Africa
Vir Biotechnology plans $200 million stock offering By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) Stock Surges to 52-Week High on Astellas Deal and Strong Earnings - MEXC
This Small-Cap Biotech Stock Is Soaring 29%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - The Malaysian Reserve
Morgan Stanley Raises Price Target for VIR to $24 with Overweigh - GuruFocus
Vir Biotechnology: Up On Prostate Data And Astellas DealI'm (Long-Term) Bullish (VIR) - Seeking Alpha
These Analysts Boost Their Forecasts On Vir Biotechnology - Benzinga
Vir Biotechnology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Astellas and Vir in $1.3B deal for CD3 T-cell engager - BioWorld MedTech
Vir Biotechnology, Inc. Q4 & Full Year 2025 Earnings: Revenue Hits $64.1M on Norgine Deal - Bayelsa Watch
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug - Barron's
VIR: Evercore ISI Group Raises Price Target to $18, Maintains Ou - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High After Earnings Beat - MarketBeat
Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN - Pharmaceutical Executive
Biotech and Big Tech Drive the Morning Narrative (2026-02-24) - Seeking Alpha
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday - Benzinga
Vir Biotechnology Secures New Collaboration and Revenue Surge - StocksToTrade
AMD, Hims & Hers, Home Depot, Kratos, Novo Nordisk, IBM, Keysight, Vir Biotechnology, and More Movers - Barron's
This Small-Cap Biotech Stock Is Soaring 26%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's
How a prostate cancer drug and a $1.7 billion deal landed at Vir BioSan Francisco Business Times - The Business Journals
Astellas Pharma, Vir Biotechnology Partner to Advance VIR-5500 - Contract Pharma
Vir Biotechnology stock hits 52-week high at 9.88 USD - Investing.com
Vir Biotechnology’s Strategic Moves Shake Up the Biotech Scene - timothysykes.com
Vir Biotechnology (VIR) Stock: Reaches 52-Week High as Three Big Catalysts Hit at Once - Blockonomi
This Small-Cap Biotech Stock Is Soaring 35%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's
Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED) - Benzinga
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Why Is Vir Biotechnology Stock Up Today? - TipRanks
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $18.00 - MarketBeat
Raymond James upgrades Vir Biotechnology stock rating on drug data - Investing.com Australia
Vir Biotechnology Stock Pre-Market (+58%): $1.7B Astellas Deal & Positive Cancer Data - Trefis
AMD, Home Depot, Novo Nordisk, Hims & Hers, Keysight, Vir Biotechnology, and More Movers - Barron's
Vir Biotechnology Secures $335 Million Deal with Astellas for VIR-5500 - Intellectia AI
Vir Biotechnology Stock Pre-Market (+58%) : Landmark Astellas Deal & Positive Cancer Data - Trefis
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Vir Biotechnology, Astellas to Advance Prostate Cancer Treatment; Says Phase 1 Trial Shows 'Promising' Anti-Tumor Activity - marketscreener.com
Vir Biotechnology Stock Hits 52-Week High TuesdayHere's Why - Bitget
Vir Biotechnology (VIR) Surges on Astellas Partnership and Stron - GuruFocus
Vir Biotechnology reports phase 1 trial results for VIR-5500 By Investing.com - Investing.com India
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Vir Biotechnology partners with Astellas on prostate cancer drug By Investing.com - Investing.com India
Vir Biotechnology Q4 2025 Earnings Call Transcript - MarketBeat
What’s Happening With VIR Stock? - Forbes
Vir Biotechnology (VIR) Announces Strategic Collaboration with A - GuruFocus
Vir Biotechnology Partners with Astellas for VIR-5500 Development - Intellectia AI
1.52%
1.68%
자본화:
|
볼륨(24시간):